Tributary Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-251,288
| Closed | -$7.19M | – | 213 |
|
|
2024
Q2 | $7.19M | Buy |
251,288
+420
| +0.2% | +$12K | 0.6% | 61 |
|
|
2024
Q1 | $7.33M | Buy |
250,868
+8,863
| +4% | +$259K | 0.6% | 62 |
|
|
2023
Q4 | $8.17M | Buy |
242,005
+59,593
| +33% | +$2.01M | 0.69% | 62 |
|
|
2023
Q3 | $5.6M | Buy |
182,412
+3,877
| +2% | +$119K | 0.53% | 61 |
|
|
2023
Q2 | $7.15M | Sell |
178,535
-3,370
| -2% | -$135K | 0.64% | 67 |
|
|
2023
Q1 | $7.42M | Buy |
181,905
+8,461
| +5% | +$345K | 0.69% | 65 |
|
|
2022
Q4 | $6.7M | Sell |
173,444
-8,523
| -5% | -$329K | 0.67% | 66 |
|
|
2022
Q3 | $9.68M | Sell |
181,967
-1,310
| -0.7% | -$69.7K | 1.02% | 53 |
|
|
2022
Q2 | $10.7M | Sell |
183,277
-5,230
| -3% | -$305K | 1.06% | 49 |
|
|
2022
Q1 | $14.4M | Buy |
188,507
+9,300
| +5% | +$710K | 1.14% | 42 |
|
|
2021
Q4 | $10.8M | Sell |
179,207
-11,069
| -6% | -$666K | 0.81% | 58 |
|
|
2021
Q3 | $10.7M | Buy |
190,276
+65,442
| +52% | +$3.66M | 0.82% | 58 |
|
|
2021
Q2 | $7.58M | Buy |
124,834
+5,186
| +4% | +$315K | 0.57% | 61 |
|
|
2021
Q1 | $8.39M | Sell |
119,648
-30,963
| -21% | -$2.17M | 0.66% | 59 |
|
|
2020
Q4 | $9.01M | Buy |
150,611
+11,208
| +8% | +$671K | 0.65% | 62 |
|
|
2020
Q3 | $8.38M | Buy |
+139,403
| New | +$8.38M | 0.72% | 57 |
|